Search
+
    SEARCHED FOR:

    HIV DRUG

    18 patent applications for HIV drug lenacapavir may delay affordable generics in India

    Gilead Sciences has filed 18 patent applications in India for lenacapavir, raising concerns among patient groups. They argue these applications may hinder the availability of affordable generic versions of the HIV drug. Consumer advocates have approached the patent office, seeking a rejection of these filings as they may constitute evergreening. If granted, these patents could remain valid until 2042, extending exclusive rights.

    Dr Reddy’s Q2 Results: Net profit falls 36% YoY to Rs 913 crore, revenue declines marginally

    Dr Reddy’s Laboratories reported a 36% year-on-year profit decline to Rs 913.4 crore in Q2 FY27, while revenue slipped 1.5%. North America weakness pressured performance, offset partly by growth in India and emerging markets, alongside biosimilar approvals and strategic partnerships.

    US FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment

    Hibsago, GSK's new hepatitis B treatment, recently secured approval from the US FDA, allowing patients to better manage their condition after therapy. This approval is vital as GSK aims for annual revenues of over £40 billion by 2031. The drug is already approved in Japan and is being assessed in China and Europe. Collaboration with Ionis Pharmaceuticals means they will receive milestone payments.

    Dr Reddy's inks pact with Gilead for once-yearly HIV prevention drug lenacapavir

    Dr Reddy's Laboratories and Gilead Sciences have signed a licensing agreement. This pact involves investigational once-yearly lenacapavir for HIV prevention. The agreement facilitates manufacturing and supply planning for 120 countries. This collaboration builds upon a previous pact for twice-yearly lenacapavir.

    DRL, Emcure get approval to make breakthrough HIV drug

    India's drug regulator has cleared the path for local lenacapavir manufacturing. Two Indian pharmaceutical companies received waivers for local clinical trials. This move will improve access to the HIV prevention injection. Lenacapavir is a breakthrough twice-yearly injection for HIV prevention. Patient groups had urged the regulator to expedite this process.

    Generic HIV drug rollout to take a hit on trial push

    India's decision to reject a waiver for local clinical trials of a new HIV drug, lenacapavir, is causing concern. Public health experts warn this will delay access to the affordable generic version for millions in India and other low-income nations. Drug maker Hetero Labs sought the waiver to speed up the launch of the treatment.

    • Lupin gets USFDA nod for generic HIV drug

      Lupin has received tentative approval from the USFDA to market a generic HIV drug in the US under PEPFAR. The drug, made at Lupin's Nagpur facility, is a generic version of ViiV Healthcare's Triumeq PD tablets and will be available to low and middle-income countries, helping pediatric HIV-1 patients. Lupin's shares were slightly down on BSE.

      Quick access to key HIV drug hinges on waiver of local clinical trials: Experts

      Faster access to HIV drug lenacapavir in India hinges on the waiver of local clinical trials. Six companies, including three from India, have non-exclusive, royalty-free licenses to produce generic versions. They must apply for waivers to supply the drug locally and in 120 low- and middle-income countries. Approval from the drug regulator is crucial.

      Dr Reddy's enters voluntary licensing deal with Gilead for long-acting HIV drug

      Dr. Reddy’s has partnered with Gilead Sciences to manufacture and market the HIV drug Lenacapavir in India and 120 other countries. The agreement includes developing Lenacapavir for both treatment and potential prevention of HIV. This collaboration aims to make this advanced treatment accessible in regions with high HIV burdens.

      Activists sound alarm bells as Gilead seeks rights over HIV drug

      Lenacapavir, a very expensive drug, is not available in India and many other countries. If the Indian Patent Office clears Gilead's patent applications, generic drug makers in India will not be allowed to produce its affordable forms.

      New 'vaccine-like' HIV drug could cost just $40: Researchers

      A new "vaccine-like" HIV drug that currently costs over $40,000 per person a year could be made for as little as $40, researchers estimated on Tuesday. "It's like having a vaccine basically," Andrew Hill, a researcher at the UK's Liverpool University, told AFP. The treatment currently costs patients over $40,000 a year in a range of countries including the United States, France, Norway and Australia.

      Scientists identify second HIV patient whose body likely rid itself of virus

      The researchers noted that some people, known as elite controllers, have immune systems that are able to suppress HIV without the need for medication.

      In Russia, a black market for HIV drug to try on coronavirus

      A black market has developed in Russia for an antiviral HIV drug explored as a possible treatment for COVID-19, the respiratory disease caused by the new coronavirus, according to sellers, HIV activists and the head of the drug's main Russian producer.

      Combination of two anti-HIV drugs proved crucial in Coronavirus treatment, Rajasthan official

      Additional Chief Secretary (Medical and Health) Rohit Kumar Singh said the patients' condition improved after they were administered the anti-HIV drugs. Three of the four patients in the state have now been declared coronavirus-free. Singh said the first two patients tested positive for the virus were an Italian couple.

      Payment delays by NACO causing HIV drugs scarcity

      Cipla, the sole producer of lopinavir/ritonavir, a combination HIV drug prescribed for paediatric patients, has stopped manufacturing it over non-clearance of arrears by NACO.

      Activists cry foul over new HIV drug monopoly

      Only one Indian drug maker, Emcure, will be allowed to sell the medicine in the Indian private market, because of a licensing agreement with Viiv Healthcare

      HIV drugs may take a toll on brain, says study

      Life-changing medicines for HIV patients may lead to forgetfulness, confusion and behavioural changes.

      Two-drug combo pill to treat HIV

      Scientists have developed a new delivery system for a combination of two HIV drugs that may serve as an effective treatment for the deadly virus.

      India’s second largest drug company Cipla has launched Qvir, a combination of four HIV drugs in one single strip.

      Hyderabad based Hetero labs through an agreement with Geneva based Medicines Patent Pool will produce four key HIV drugs developed by Gilead Lifesciences.

      An independent mechanism that protects the patent rights of Big Pharma while allowing generic firms to sell cheap, copycat HIV drugs to poor countries.

      India has rejected American drugmaker Bristol-Myers Squibb's (BMS) patent application for one of its HIV drugs, allowing local drugmakers to make and sell the medicine in the country.

      Indian Pharma Co claims it can sell HIV drug at one-fifth the price.

      Besides I-MAK, a few local HIV drug makers such as Cipla and US-based Mylan-owned Matrix Laboratories had also opposed Abbott's attempt to get the patent in India.

      In a bid to make anti-cancer and HIV drugs more accessible, the government is planning to ask public sector drug makers to manufacture anti-HIV drugs.

      HIV patient group-Delhi Network of Positive People (DNP+)-has filed a post-grant opposition against Swiss major Roche’s patent for its HIV drug Valganciclovir at the Chennai Patent office.

      In what could strengthen Cipla's patent challenge against global major Gilead Science's patent application for its key HIV drug, Viread, the US Patent & Trademark office has rejected Viread patent application in the US.

      HIV treatment in India could get costlier as global pharma cos have started securing patents for drugs used to treat AIDS and related diseases.

      JB Chemicals & Pharmaceuticals Ltd on Friday said it has signed a non-exclusive license agreement with US-based Gilead Sciences Inc to manufacture and distribute a generic version of the anti-HIV drug Tenofovir Disoproxil Fumarate.

      Load More
    The Economic Times
    BACK TO TOP